← FDA DRUG APPROVALS
FDA ANDA · ANDA077183
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE
Sponsor: DR REDDYS LABS INC
APPLICATION
ANDA077183
TYPE
ANDA
ORIGINAL APPROVAL
2010-04-15
LATEST ACTION
2019-11-22
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDEPrescription
AMLODIPINE BESYLATE EQ 10MG BASE, BENAZEPRIL HYDROCHLORIDE 20MG · CAPSULE · ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDEPrescription
AMLODIPINE BESYLATE EQ 5MG BASE, BENAZEPRIL HYDROCHLORIDE 10MG · CAPSULE · ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDEPrescription
AMLODIPINE BESYLATE EQ 5MG BASE, BENAZEPRIL HYDROCHLORIDE 20MG · CAPSULE · ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDEPrescription
AMLODIPINE BESYLATE EQ 2.5MG BASE, BENAZEPRIL HYDROCHLORIDE 10MG · CAPSULE · ORAL
Approval history
2019-11-22Labeling · Supplement 13 · standardAP
2016-01-04Labeling · Supplement 12 · standardAP
2016-01-04Labeling · Supplement 11 · standardAP
2014-10-26Labeling · Supplement 6 · standardAP
2012-02-23Labeling · Supplement 5AP
2011-12-12Labeling · Supplement 4AP
2011-10-27Labeling · Supplement 3AP
2011-02-14Labeling · Supplement 2AP
2010-06-04Labeling · Supplement 1AP
2010-04-15OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.